FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2165630767> ?p ?o ?g. }

• W2165630767 endingPage "537" @default.
• W2165630767 startingPage "527" @default.
• W2165630767 abstract "BackgroundCediranib is a highly potent vascular endothelial growth factor (VEGF) signalling inhibitor with activity against VEGF receptors 1, 2 and 3. This Phase II, randomised, double-blind, parallel-group study compared the efficacy of cediranib with placebo in patients with metastatic or recurrent clear cell renal cell carcinoma who had not previously received a VEGF signalling inhibitor.MethodsPatients were randomised (3:1) to cediranib 45 mg/day or placebo. The primary objective was comparison of change from baseline in tumour size after 12 weeks of therapy. Secondary objectives included response rate and duration, progression-free survival (PFS) and safety and tolerability. Patients in the placebo group could cross over to open-label cediranib at 12 weeks or earlier if their disease had progressed. This study has been completed and is registered with ClinicalTrials.gov, number NCT00423332.FindingsPatients (n = 71) were randomised to receive cediranib (n = 53) or placebo (n = 18). The primary study outcome revealed that, after 12 weeks of therapy, there was a significant difference in mean percentage change from baseline in tumour size between the cediranib (–20%) and placebo (+20%) arms (p < 0.0001). Eighteen patients (34%) on cediranib achieved a partial response and 25 (47%) experienced stable disease. Cediranib treatment prolonged PFS significantly compared with placebo (hazard ratio (HR) = 0.45, 90% confidence interval: 0.26–0.76, p = 0.017; median PFS 12.1 versus 2.8 months). The most common adverse events in patients receiving cediranib were diarrhoea (74%), hypertension (64%), fatigue (58%) and dysphonia (58%).InterpretationCediranib monotherapy demonstrated significant evidence of antitumour activity in patients with advanced renal cell carcinoma. The adverse event profile was consistent with previous studies of cediranib 45 mg." @default.
• W2165630767 created "2016-06-24" @default.
• W2165630767 creator A5002598093 @default.
• W2165630767 creator A5032541182 @default.
• W2165630767 creator A5032816632 @default.
• W2165630767 creator A5041689299 @default.
• W2165630767 creator A5062519984 @default.
• W2165630767 creator A5062742458 @default.
• W2165630767 creator A5063293745 @default.
• W2165630767 creator A5080362625 @default.
• W2165630767 creator A5083924487 @default.
• W2165630767 creator A5084791255 @default.
• W2165630767 creator A5085499539 @default.
• W2165630767 creator A5087689900 @default.
• W2165630767 date "2012-03-01" @default.
• W2165630767 modified "2023-09-28" @default.
• W2165630767 title "Cediranib monotherapy in patients with advanced renal cell carcinoma: Results of a randomised phase II study" @default.
• W2165630767 cites W1978083619 @default.
• W2165630767 cites W1980013575 @default.
• W2165630767 cites W1999966467 @default.
• W2165630767 cites W2003888937 @default.
• W2165630767 cites W2017912212 @default.
• W2165630767 cites W2043837703 @default.
• W2165630767 cites W2078797757 @default.
• W2165630767 cites W2097373408 @default.
• W2165630767 cites W2099022883 @default.
• W2165630767 cites W2103506609 @default.
• W2165630767 cites W2106787323 @default.
• W2165630767 cites W2121534113 @default.
• W2165630767 cites W2123769946 @default.
• W2165630767 cites W2129851137 @default.
• W2165630767 cites W2137758263 @default.
• W2165630767 cites W2139248078 @default.
• W2165630767 cites W2140765540 @default.
• W2165630767 cites W2143695921 @default.
• W2165630767 cites W2147535764 @default.
• W2165630767 cites W2149456801 @default.
• W2165630767 cites W2153331460 @default.
• W2165630767 cites W2154056804 @default.
• W2165630767 cites W2162424705 @default.
• W2165630767 cites W2166788033 @default.
• W2165630767 cites W2170706701 @default.
• W2165630767 cites W2171046634 @default.
• W2165630767 doi "https://doi.org/10.1016/j.ejca.2011.12.022" @default.
• W2165630767 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22285180" @default.
• W2165630767 hasPublicationYear "2012" @default.
• W2165630767 type Work @default.
• W2165630767 sameAs 2165630767 @default.
• W2165630767 citedByCount "70" @default.
• W2165630767 countsByYear W21656307672012 @default.
• W2165630767 countsByYear W21656307672013 @default.
• W2165630767 countsByYear W21656307672014 @default.
• W2165630767 countsByYear W21656307672015 @default.
• W2165630767 countsByYear W21656307672016 @default.
• W2165630767 countsByYear W21656307672017 @default.
• W2165630767 countsByYear W21656307672018 @default.
• W2165630767 countsByYear W21656307672020 @default.
• W2165630767 countsByYear W21656307672021 @default.
• W2165630767 countsByYear W21656307672022 @default.
• W2165630767 countsByYear W21656307672023 @default.
• W2165630767 crossrefType "journal-article" @default.
• W2165630767 hasAuthorship W2165630767A5002598093 @default.
• W2165630767 hasAuthorship W2165630767A5032541182 @default.
• W2165630767 hasAuthorship W2165630767A5032816632 @default.
• W2165630767 hasAuthorship W2165630767A5041689299 @default.
• W2165630767 hasAuthorship W2165630767A5062519984 @default.
• W2165630767 hasAuthorship W2165630767A5062742458 @default.
• W2165630767 hasAuthorship W2165630767A5063293745 @default.
• W2165630767 hasAuthorship W2165630767A5080362625 @default.
• W2165630767 hasAuthorship W2165630767A5083924487 @default.
• W2165630767 hasAuthorship W2165630767A5084791255 @default.
• W2165630767 hasAuthorship W2165630767A5085499539 @default.
• W2165630767 hasAuthorship W2165630767A5087689900 @default.
• W2165630767 hasBestOaLocation W21656307671 @default.
• W2165630767 hasConcept C126322002 @default.
• W2165630767 hasConcept C141071460 @default.
• W2165630767 hasConcept C142724271 @default.
• W2165630767 hasConcept C143998085 @default.
• W2165630767 hasConcept C197934379 @default.
• W2165630767 hasConcept C204787440 @default.
• W2165630767 hasConcept C207103383 @default.
• W2165630767 hasConcept C27081682 @default.
• W2165630767 hasConcept C2777472916 @default.
• W2165630767 hasConcept C2778375690 @default.
• W2165630767 hasConcept C44249647 @default.
• W2165630767 hasConcept C71924100 @default.
• W2165630767 hasConcept C90924648 @default.
• W2165630767 hasConceptScore W2165630767C126322002 @default.
• W2165630767 hasConceptScore W2165630767C141071460 @default.
• W2165630767 hasConceptScore W2165630767C142724271 @default.
• W2165630767 hasConceptScore W2165630767C143998085 @default.
• W2165630767 hasConceptScore W2165630767C197934379 @default.
• W2165630767 hasConceptScore W2165630767C204787440 @default.
• W2165630767 hasConceptScore W2165630767C207103383 @default.
• W2165630767 hasConceptScore W2165630767C27081682 @default.
• W2165630767 hasConceptScore W2165630767C2777472916 @default.
• W2165630767 hasConceptScore W2165630767C2778375690 @default.
• W2165630767 hasConceptScore W2165630767C44249647 @default.

• next